People · Operator
Named in public records as an officer, director or promoter · active 2015–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Genomenon, Inc. | — | Biotechnology | Series B | $28.8M | $41.9M | 2015 |
Mark Kiel at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark Kiel on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Klein | 1 | 9 |
| Michael Gross | 1 | 9 |
| Charles Moret | 1 | 4 |
| Patricia Glaza | 1 | 3 |
| David Gregorka | 1 | 2 |
| Sean Kearney | 1 | 2 |
| Steve Schwartz | 1 | 2 |
| Sonya Sepahban | 1 | 1 |
| Eli Salembier | 1 | 1 |
| Sam Globus | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.